# Synchron

> Synchron develops an investigational endovascular brain-computer interface for people with severe motor impairment. Its Stentrode electrode array reaches a brain blood vessel through the jugular vein, records motor-intent signals, and enables digital device control through a decoder and accessibility software. Human studies in Australia and the United States underpin a venture-funded effort to commercialize the platform.

- **Founded:** 2012
- **Headquarters:** New York, United States
- **Founders:** Thomas Oxley (Co-founder and CEO), Nicholas Opie (Co-founder and CTO)
- **Products:** Stentrode BCI system, Apple BCI-HID integration, Chiral AI
- **Notable:** Australian first-in-human clinical program began in 2019., FDA Breakthrough Device designation in 2020 and Investigational Device Exemption in 2021., Peer-reviewed SWITCH study reported safety and feasibility in four participants in 2023.

## Products & services

- **Stentrode BCI system** — Investigational electrode array delivered through the jugular vein to a brain blood vessel, linked to implanted telemetry and an external decoder for digital control. Human clinical program began in 2019.
- **Apple BCI-HID integration** — Bluetooth-based input integration with Apple Switch Control, demonstrated on an iPad by a COMMAND participant.
- **Chiral AI** — Announced neural-data foundation-model roadmap, including self-supervised learning and context-aware decoding; future capabilities remain development goals.

## Achievements

- Australian first-in-human clinical program began in 2019.
- FDA Breakthrough Device designation in 2020 and Investigational Device Exemption in 2021.
- Peer-reviewed SWITCH study reported safety and feasibility in four participants in 2023.
- Six COMMAND participants met the primary one-year safety endpoint, according to September 2024 company results.
- Demonstrated native BCI-driven iPad use in August 2025.
- Company reported US$345 million total funding after its November 2025 round.

## Latest updates

- **2026-04** — Listed in TIME’s New Frontiers company selection, linked from Synchron’s news page.
- **2026-03** — WIRED published a five-year implant follow-up feature; Synchron’s news page also lists Fast Company data-science recognition.
- **2025-11** — Raised US$200 million Series D; stated total funding reached US$345 million.
- **2025-08** — Released a native thought-controlled iPad demonstration with COMMAND participant Mark.
- **2025-03** — Announced Chiral AI roadmap and demonstrated a smart-home interaction using Holoscan and Vision Pro.

## Links

- Website: https://synchron.com/
- LinkedIn: https://www.linkedin.com/company/synchron-inc-/
- Twitter/X: https://twitter.com/synchroninc
- YouTube: https://www.youtube.com/c/SynchronInc
- Instagram: https://www.instagram.com/synchroninc/
- Facebook: https://www.facebook.com/synchroninc

---

Profile page: https://yespress.io/synchron
Published by YesPress — https://yespress.io
Last updated: 2026-10-05